ArticleJournal of clinical medicine2022
Effectiveness and Safety of High-Dose Dual Therapy: Results of the European Registry on the Management of
Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Network meta-analysis of treatment interventions forFrontiers in pharmacology · 2024Pooled it
- Review Article: Classic Bismuth Quadruple Therapy for Helicobacter pylori Infection-Questions Focused on Clinical Practice.Alimentary pharmacology & therapeutics · 2026Review
- VTH BRAZILIAN CONSENSUS CONFERENCE ON HELICOBACTER PYLORI INFECTION.Arquivos de gastroenterologia · 2026Article
- Update on the Management of Helicobacter pylori Infection in Children and Adolescents.Current gastroenterology reports · 2025Review
- Tegoprazan-Amoxicillin Dual Therapy for Clarithromycin-ResistantMicroorganisms · 2025Article
- Role of Vonoprazan-Amoxicillin Dual Therapy in Pediatric RefractoryACG case reports journal · 2025Article
- Comparative efficacy and safety of vonoprazan versus esomeprazole-based high-dose dual therapies for first-lineTherapeutic advances in gastroenterology · 2025Article
- Current and Future Perspectives on the Management ofAntibiotics (Basel, Switzerland) · 2024Review
- Article
- Success ofJournal of the Canadian Association of Gastroenterology · 2024Article
- Helicobacter pylori infection.Nature reviews. Disease primers · 2023Review
- Rescue therapy for refractoryTherapeutic advances in gastroenterology · 2023Review
- European Registry onFrontiers in gastroenterology (Lausanne, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRandomized clinical trials and meta-analyses, primarily from Asian countries, have reported good effectiveness with high-dose dual therapy (HDDT) including a proton pump inhibitor (PPI) and amoxicillin when prescribed as
methodsAn international, multicenter, prospective non-interventional Registry (Hp-EuReg) aimed to evaluate the decisions and outcomes of
resultsOverall HDDT effectiveness was 52% (per-protocol) and 51% (modified intention-to-treat). First-line and rescue treatment lines were equally effective, but the effectiveness was worse when patients had previously received metronidazole, tetracycline, or rifabutin. Adding bismuth to HDDT in rescue treatment did not yield better results. The incidence of adverse events was 30%, diarrhea being the most common (20% of patients); no serious adverse events were reported.
conclusionAlthough HDDT is safe and has good compliance, it is not a good option in European first-line or rescue
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.